November 19, 2026
Highlights from the Fall Group Meeting, efforts to improve clinical trial efficiency, and promising developments in cancer vaccines
November 19, 2026
This phase 2/3 clinical trial compares ivonescimab plus chemotherapy with standard initial treatment
November 19, 2026
Dr. Janice Mehnert highlights promising phase 3 results for a personalized mRNA-based therapy designed to help prevent high-risk melanoma from returning after surgery
November 19, 2026
In an annual evaluation, 35 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
November 19, 2026
This phase 3 study compares BRAF-targeted therapy (dabrafenib-trametinib) to TKI therapy (cabozantinib) in patients with disease progression after standard treatments
November 19, 2026
The latest findings in leukemia, pancreas cancer, and throat cancer
November 19, 2026
Timely information about research presented at medical meetings, recognition of research leaders, and more
![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)







